Welcome to Paid Research Studies




  • Conditions:   HIV;   Acquired Immunodeficiency Syndrome
    Interventions:   Behavioral: ESTEEM;   Behavioral: CMHT;   Behavioral: VCT
    Sponsor:   Yale University
    Recruiting - verified October 2016

  • Condition:   Substance-related Disorders
    Intervention:   Behavioral: Implementation Facilitation
    Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA)
    Recruiting - verified July 2017

  • Condition:   HIV
    Intervention:   Drug: PRO 140
    Sponsor:   CytoDyn, Inc.
    Recruiting - verified February 2017

  • Condition:   HIV
    Interventions:   Drug: ibalizumab;   Drug: Optimized Background Regimen
    Sponsors:   TaiMed Biologics Inc.;   Westat
    Recruiting - verified April 2017

  • Condition:   Human Immunodeficiency Virus
    Intervention:   Other: Anti-Retroviral Treatment and Access to Services (ARTAS)
    Sponsors:   Centers for Disease Control and Prevention;   Connecticut State, Department of Mental Health and Addiction Services;   Massachusetts Department of Health;   Philadelphia Department of Public Health
    Recruiting - verified January 2017

  • Conditions:   AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2016

  • Condition:   HIV
    Interventions:   Drug: PRO 140;   Drug: Placebo;   Drug: Optimized Background Regimen
    Sponsors:   CytoDyn, Inc.;   Amarex Clinical Research
    Recruiting - verified November 2016

  • Condition:   HIV
    Intervention:   Genetic: SB-728mR-HSPC Infusion 3 days following busulfan conditioning
    Sponsors:   City of Hope Medical Center;   Sangamo Therapeutics
    Recruiting - verified June 2017

  • Conditions:   HIV Infections;   Cardiovascular Diseases
    Interventions:   Drug: Pitavastatin;   Drug: Placebo
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
    Recruiting - verified June 2017

  • Conditions:   Risk Behavior;   Medication Adherence;   HIV
    Interventions:   Behavioral: 3H+ (Holistic Health for HIV);   Behavioral: HHRP+ (Holistic Health Recovery Program)
    Sponsors:   University of Connecticut;   National Institute on Drug Abuse (NIDA);   Yale University;   APT Foundation, Inc.
    Recruiting - verified October 2016

  • Condition:   HIV
    Interventions:   Drug: antiretroviral therapy;   Behavioral: cell phone reminders;   Behavioral: contingency management for adherence
    Sponsors:   UConn Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified June 2017

  • Condition:   HIV Infections
    Interventions:   Drug: atazanavir/cobicistat;   Drug: darunavir/ritonavir;   Drug: darunavir/cobicistat;   Drug: etravirine;   Drug: elvitegravir/cobicistat;   Drug: dolutegravir;   Drug: tenofovir alafenamide fumarate (TAF);   Drug: TAF/cobicistat;   Drug: TAF/ritonavir;   Drug: efavirenz;   Drug: lopinavir/ritonavir;   Drug: nevirapine;   Drug: rifampicin;   Drug: ethambutol;   Drug: isoniazid;   Drug: pyrazinamide;   Drug: rifampicin;   Drug: kanamycin;   Drug: amikacin;   Drug: capreomycin;   Drug: moxifloxacin;   Drug: levofloxacin;   Drug: ofloxacin;   Drug: ethionamide/prothionamide;   Drug: terizidone/cycloserine;   Drug: para-aminosalicylic acid (PAS);   Drug: high dose isoniazid (INH);   Drug: bedaquiline;   Drug: clofazamine;   Drug: delamanid;   Drug: linezolid;   Drug: pretomanid;   Drug: atazanavir/ritonavir/tenofovir;   Drug: ethinyl estradiol oral contraceptive;   Drug: etonogestrel implant
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified May 2017